Breathwork-assisted Treatment for Cannabis Use Disorder

February 1, 2024 updated by: Elias Dakwar

Breathwork-assisted Treatment for Cannabis Use Disorder: A Proof-of-concept Study

The purpose of this proof-of-concept study is to evaluate the safety, feasibility and acceptability of a breathwork workshop intervention in individuals with cannabis use disorder.

Study Overview

Detailed Description

This study will test a 1-week breathwork workshop for treatment-seeking adults with a diagnosis of cannabis use disorder. The intervention consists of an enhanced breathing session with evocative music to facilitate experiencing non-ordinary states of consciousness, in addition to brief therapeutic interventions based on Motivational Interviewing and Mindfulness-based Relapse Prevention (MBRP). The primary aim is to test the acceptability, feasibility and safety of enhanced breathwork in a therapeutic framework for cannabis use disorder. In addition, the investigators seek to understand the phenomenology of breathwork that may explain any change related to addictive behaviors, as well as biological changes that occur during the breathwork session through heart rate variability and electroencephalography.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18-70 years of age
  • Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for active cannabis use disorder.
  • Seeking treatment for their cannabis use

Exclusion Criteria:

  • Meets DSM-V criteria for schizophrenia or any psychotic illness or any dissociative disorder (Dissociative identity disorder, Dissociative amnesia, Depersonalization/derealization disorder).
  • Active substance use disorder except for cannabis, nicotine, and caffeine.
  • History of severe withdrawal symptoms (i.e withdrawal seizures).
  • History of dementia, epilepsy or seizures, cardiac arrhythmia, pacemaker/defibrillator, heart failure, asthma, panic disorder and other respiratory illnesses (ie: COPD).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Breathwork group
Treatment-seeking individuals with cannabis use disorder who will participate in the 1-week breathwork workshop.
Participants will complete 1.5 hours of breathwork session in addition to a total of 6 hours of brief psychotherapeutic intervention in a span of 1 week. The therapy sessions will occur both before and after the breathing session.
Other Names:
  • Enhanced breathing session + Brief psychotherapeutic intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of the breathwork session
Time Frame: One week after the breathing session.
Acceptability of the breathwork intervention through self-reported questionnaires.
One week after the breathing session.
Safety of the breathing session
Time Frame: 24 hours after the breathing session.
Occurrence of adverse effects through a self-reported questionnaire.
24 hours after the breathing session.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Cue Reactivity
Time Frame: From baseline to 1 month after the breathing session.
Serial visual analogue scale for craving elicited by cannabis use.
From baseline to 1 month after the breathing session.
Change in Motivation to Quit
Time Frame: From baseline to 1 month after the breathing session.
Measured with the "Stages of Change Readiness and Treatment Eagerness Scale."
From baseline to 1 month after the breathing session.
Change in cannabis use
Time Frame: From baseline to 1 month after the breathing session.
Changes in cannabis use as measured by the Timeline Followback.
From baseline to 1 month after the breathing session.
Phenomenology of breathwork #1
Time Frame: 24 hours after the breathing session
Subjective experiences during the breathing session will be assessed with the 30-item Mystical Experience Questionnaire.
24 hours after the breathing session
Phenomenology of breathwork #2
Time Frame: Obtained 24 hours after the breathing session
Subjective experiences during the breathing session will be assessed with the Emotional Breakthrough Inventory.
Obtained 24 hours after the breathing session
Heart Rate Variability
Time Frame: Measured during breathing session
Polar (H10) chest strap
Measured during breathing session
Electroencephalographic changes
Time Frame: Measured during breathing session
Electroencephalograpy cap
Measured during breathing session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Silvia J Franco Corso, M.D, New York State Psychiatric Institute/ Columbia University Medical Center
  • Study Chair: Elias Dakwar, M.D, New York State Psychiatric Institute/ Columbia University Medical Center
  • Study Director: Kate O'Malley, M.A, New York State Psychiatric Institute/ Columbia University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 6, 2022

Primary Completion (Estimated)

August 1, 2024

Study Completion (Estimated)

August 1, 2024

Study Registration Dates

First Submitted

December 30, 2021

First Submitted That Met QC Criteria

February 1, 2022

First Posted (Actual)

February 2, 2022

Study Record Updates

Last Update Posted (Actual)

February 2, 2024

Last Update Submitted That Met QC Criteria

February 1, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Addiction

Clinical Trials on Breathwork workshop

3
Subscribe